<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407784</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2006-103</org_study_id>
    <secondary_id>C05.2151</secondary_id>
    <secondary_id>EudraCT nr: 2006-006618-13</secondary_id>
    <nct_id>NCT00407784</nct_id>
  </id_info>
  <brief_title>Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.</brief_title>
  <official_title>Aldosterone-Renin Ratio to Diagnose Primary Aldosteronism in a Population of Patients With Therapy-Resistant Hypertension: Test Characteristics, Diagnostic Value and Predictive Value for Antihypertensive Treatment. The Dutch ARRAT Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <brief_summary>
    <textblock>
      This study aims to evaluate the diagnostic value of the Aldosterone-Renin Ratio (ARR)as a
      screening test for primary aldosteronism among hypertensives. The test characteristics will
      be studied. Furthermore, the effect of eplerenone, a selective aldosterone-receptor
      antagonist will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although primary aldosteronism (PA) was formerly seen as a rare cause of hypertension, this
      condition is now thought to be the commonest cause of secondary hypertension, with the
      prevalence ranging up to 10-15 % of all hypertensives. Identification of patients with PA
      allows for specific treatment, for instance unilateral adrenalectomy in case of an
      aldosterone-producing adenoma or the administration of an aldosterone-receptor antagonist in
      case of bilateral adrenal hyperplasia.

      Since the introduction of the aldosterone-renin ratio (ARR) as a screening tool for PA in
      1981, there has been considerable debate about the diagnostic value. The values for
      aldosterone and renin are highly dependent on many factors, including posture, time of day
      and medication. Also, the cut-off values for the identification of PA remain controversial.

      This study aims to evaluate the test characteristics of the ARR in a population of patients
      with therapy-resistant hypertension, the dependence of the ARR on medication type and the
      predictive value on the response on eplerenone, a selective aldosterone-receptor antagonist.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date>November 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>500</enrollment>
  <condition>Hyperaldosteronism</condition>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eplerenone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-65 years

          -  blood pressure above 140 mmHg systolic and above 90 mmHg diastolic

          -  use of at least 2 antihypertensive drugs

        Exclusion Criteria:

          -  known cause of hypertension, including white-coat hypertension

          -  severe renal failure (kreat &gt; 200 umol/l)

          -  BMI above 32 kg/m2

          -  poorly regulated diabetes mellitus (HbA1C &gt; 8.0 %)

          -  heart failure

          -  stroke or myocardial infarction within 6 months before inclusion

          -  angina pectoris

          -  pregnancy

          -  neoplastic disease, within 5 years before inclusion

          -  alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.H. van den Meiracker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter Jansen, MD</last_name>
    <phone>+31(0)-4632196</phone>
    <email>p.jansen.1@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A.H. van den Meiracker, MD, PhD</last_name>
    <phone>+31(0)-4634220</phone>
    <email>a.vandenmeiracker@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academical Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VU medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IJsselland Hospital</name>
      <address>
        <city>Capelle aan de IJssel</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatrix Hospital</name>
      <address>
        <city>Gorinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ikazia Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MCRZ, lokation Zuider/Clara</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oogziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vlietland Hospital</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruwaard van Putten Hospital</name>
      <address>
        <city>Spijkenisse</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Twee Steden Ziekenhuis</name>
      <address>
        <city>Waalwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981 Nov;141(12):1589-93.</citation>
    <PMID>7030245</PMID>
  </reference>
  <reference>
    <citation>Gordon RD, Klemm SA, Stowasser M, Tunny TJ, Storie WJ, Rutherford JC. How common is primary aldosteronism? Is it the most frequent cause of curable hypertension? J Hypertens Suppl. 1993 Dec;11(5):S310-1.</citation>
    <PMID>8158400</PMID>
  </reference>
  <reference>
    <citation>Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003 May;17(5):349-52.</citation>
    <PMID>12756408</PMID>
  </reference>
  <reference>
    <citation>Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003 Nov;21(11):2149-57.</citation>
    <PMID>14597859</PMID>
  </reference>
  <reference>
    <citation>Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005 Feb;51(2):386-94.</citation>
    <PMID>15681560</PMID>
  </reference>
  <reference>
    <citation>Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens. 2006 Apr;24(4):737-45.</citation>
    <PMID>16531803</PMID>
  </reference>
  <reference>
    <citation>Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004 May;22(5):863-9. Review.</citation>
    <PMID>15097219</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2006</study_first_submitted>
  <study_first_submitted_qc>December 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2006</study_first_posted>
  <last_update_submitted>March 6, 2007</last_update_submitted>
  <last_update_submitted_qc>March 6, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2007</last_update_posted>
  <keyword>primary aldosteronism</keyword>
  <keyword>hypertension</keyword>
  <keyword>aldosteron-renin ratio</keyword>
  <keyword>eplerenone</keyword>
  <keyword>aldosteron-receptor antagonist</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

